Last reviewed · How we verify
Lavopa (RITODRINE)
Lavopa (Ritodrine) is a small molecule drug developed by HOSPIRA that targets the beta-2 adrenergic receptor. It is used to treat premature labor and was FDA approved in 1991. As an off-patent medication, it is available as a generic from multiple manufacturers. Key safety considerations include its short half-life of 2.6 hours and moderate bioavailability of 30%. Lavopa's commercial status allows for generic competition.
At a glance
| Generic name | RITODRINE |
|---|---|
| Sponsor | Pfizer |
| Drug class | ritodrine |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1991 |
Approved indications
- Premature labor
Common side effects
Key clinical trials
- Comparative Study Between Nifedipine and Ritodrine as Maintenance Tocolytic Therapy in Preterm Labor (PHASE4)
- Efficacy and Safety of MgSO4 as Tocolytics Compared to Ritodrine in Preterm Labor (NA)
- Tocolysis in Prevention of Preterm Labor (PHASE4)
- Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself (PHASE1)
- Ritodrine in Oral Maintenance of Tocolysis After Active Preterm Labor (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lavopa CI brief — competitive landscape report
- Lavopa updates RSS · CI watch RSS
- Pfizer portfolio CI